NCT01265914View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

August 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

FP-01.1

Ascending doses of FP-01.1 will be administered

BIOLOGICAL

placebo

Trial Locations (1)

Unknown

Hammersmith Medicines Research Ltd, London

Sponsors
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

lead

Immune Targeting Systems Ltd

INDUSTRY